Quantification of the prevalence of harms in healthcare related to drug treatment: reflections regarding the use of definitions developed for other settings to estimate the magnitude of the problem
European Journal of Clinical Pharmacology · 2025
DOI: 10.1007/s00228-024-03766-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2025. Verfasst von Susanna M Wallerstedt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, Box 431, SE-405 30, Gothenburg, Sweden. susanna.wallerstedt@pharm.gu.se. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Pharmacovigilance. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Gothenburg.
Abstract (Originalsprache)
The prevalence of harms in healthcare related to drug treatment is often quantified using terms developed for pharmacovigilance and pharmaceutical care. In this overview, we guide through the definitions and the settings for which they were developed, with the underlying intention to facilitate the interpretation of hitherto available research intended to contribute information regarding the magnitude of the problem in healthcare and to provide guidance for future research. To start, the regulatory/academic definitions of an adverse drug reaction (ADR) and a drug-related problem (DRP) are considerably broader than a literal interpretation would suggest. ADRs are defined for the pharmacovigilance setting, and for drug safety reasons the opposite of the benefit of the doubt rules; if it cannot be excluded that the medication has caused or contributed to an event, it will be a suspected ADR. DRPs represent the pharmaceutical care setting where every aspect is included that could potentially be problematic; a manifested problem is not required. When quantifying the prevalence of harms related to drug treatment in the healthcare setting, however, it may not be considered reasonable to count every circumstance that could possibly be an ADR or everything that could potentially be problematic. Therefore, definitions developed for the pharmacovigilance and the pharmaceutical care settings are not fully applicable to estimate the magnitude of drug treatment problems in healthcare. Proposed guidance for the future includes cautious interpretation of research results, as well as a conscious choice of definitions according to purpose and tempered reporting in research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, Box 431, SE-405 30, Gothenburg, Sweden. susanna.wallerstedt@pharm.gu.se.
- HTA-Centrum, Sahlgrenska University Hospital, Gothenburg, Sweden. susanna.wallerstedt@pharm.gu.se.
- The NEPI Foundation - Swedish Network for Pharmacoepidemiology, Linköping, Sweden.
- Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Förderung
- University of Gothenburg
Zitieren
APA
Wallerstedt, S. M., & Hoffmann, M. (2025). Quantification of the prevalence of harms in healthcare related to drug treatment: reflections regarding the use of definitions developed for other settings to estimate the magnitude of the problem. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03766-7
Vancouver
Wallerstedt SM, Hoffmann M. Quantification of the prevalence of harms in healthcare related to drug treatment: reflections regarding the use of definitions developed for other settings to estimate the magnitude of the problem. European Journal of Clinical Pharmacology. 2025. doi:10.1007/s00228-024-03766-7
BibTeX
@article{Wallerstedt2025,
author = {Wallerstedt, Susanna M and Hoffmann, Mikael},
title = {Quantification of the prevalence of harms in healthcare related to drug treatment: reflections regarding the use of definitions developed for other settings to estimate the magnitude of the problem},
journal = {European Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1007/s00228-024-03766-7}
}
EUVIMED